Showing 1 - 8 results of 8 for search 'Bengt Hoepken', query time: 0.27s Refine Results
  1. 1
    Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW
    Get full text
    Article
    Save to List
    Saved in:
Search Tools: RSS Feed – Email Search